-transparent.png){kind=logo}
Amrinone is a cardiotonic agent associated with reversible thrombocytopenia in 20% to 50% of patients. The mechanism of thrombocytopenia is not known and it is not clear whether this effect represents a high-frequency idiosyncratic reaction or an overt manifestation of a toxic effect on platelet survival. We prospectively evaluated the effect of oral amrinone on platelet function and survival in seven subjects who participated in a clinical trial of chronic oral amrinone therapy. There was no consistent effect on either platelet function or platelet survival. Data suggest that amrinone does not have a uniform effect on platelet survival and that the development of thrombocytopenia may represent an idiosyncratic reaction.
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
January 1981,
Prostaglandins and medicine,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
March 1984,
British journal of clinical pharmacology,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
January 1993,
Stroke,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
June 1988,
FEBS letters,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
October 1995,
Clinical and experimental immunology,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
March 2007,
Platelets,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
August 1984,
Thrombosis research,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
August 1986,
Circulation,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
February 1986,
Research communications in chemical pathology and pharmacology,
J T Brandt, and
L Miller, and
J Hermiller, and
D V Unverferth, and
C V Leier
December 1976,
Clinical pharmacology and therapeutics,
